Citalopram and Stress Reactivity

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-10-11

Study Completion Date

2020-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is investigating whether acute administration of citalopram is associated with a decrease in stress reactivity in healthy volunteers, compared to placebo administration. Using a parallel-group double-blind design, participants will be randomised to receive either an acute dose of citalopram or placebo. All participants will have come in for a screening visit. On the day of the research visit (following drug administration) participants will have completed a number of widely used computer-based cognitive tasks measuring emotional processing biases. They will then complete the Oxford Cognition Stress Task, a web-based acute stress induction paradigm, which is designed to induce mild transient increases in stress and arousal. Identifying early changes in stress reactivity following antidepressant treatment will increase the investigator's knowledge of how antidepressants operate, and provide putative targets to identify early response to antidepressants.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Antidepressants, Emotions and Personality

NCT01946607

Antidepressive Agents, Second-Generation

COMPLETED NA

Citalopram and Self Emotional Processing

NCT04169230

Molecular Mechanisms of Pharmacological Action Depression Depressive Disorder +3 more

UNKNOWN NA

7T Amygdala and Citalopram Study

NCT06412315

Emotional Processing Cognition Mood Disorders +2 more

RECRUITING NA

Serotonin, Anxiety and Visceral Sensation

NCT06212284

Healthy

COMPLETED NA

Double Blind Randomized, Monocentric, Cross-over, Placebo-controlled Study to Evaluate the Effect of Citalopram on Motivation

NCT02113943

Normal Volunteers

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In the Oxford Cognition Stress Task (OCST), participants are presented with a series of mental arithmetic, verbal (anagrams) and visuospatial (visual search) challenges on a computer screen. There is a time limit for completing each challenge, which is displayed on the screen as a time bar. To induce a high failure rate, the timing and difficulty of the challenges is automatically varied to ensure participants are correctly complete only 20-40% of the challenges within the time, and some of the verbal challenges (anagrams) are impossible to solve. Participants are given feedback on their performance on the screen which indicates that they are performing badly. Heart rate will be measured continuously during the OCST, and during pre- and post- task periods. Baseline and post-OCST measures of blood pressure and samples of saliva (for cortisol analysis) will be taken. Participants will also complete Visual Analogue Scales pre- and post-OCST to give a subjective measure of stress and mood. Participants will not be told the extent to which becoming stressed (and finding the task difficult) is intended. At the end of the test session, participants will be fully debriefed as to the nature of the OCST.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression Depressive Disorder Mental Disorder Antidepressive Agents Cognition Stress

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Following the screening, eligible participants will be randomised to receive either a single 20mg oral dose of citalopram or a matched lactose placebo tablet using an online randomisation tool. Note that the study is not assessing the safety or efficacy of citalopram, rather it is using citalopram to understand the role of serotonin in stress reactivity.

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Drug: Citalopram

20mg oral dose of citalopram (tablet encapsulated in opaque capsule)

Group Type EXPERIMENTAL

Citalopram

Intervention Type DRUG

Single dose administration of citalopram (20mg)

Placebo

Lactose placebo (tablet encapsulated in opaque capsule)

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Lactose placebo tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Citalopram

Single dose administration of citalopram (20mg)

Intervention Type DRUG

Placebo

Lactose placebo tablet

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or Female
* Aged 18 -45 years
* Fluent in written and spoken English at a sufficient level to understand and complete the tasks
* Body Mass Index (BMI) 18-30
* Participant is willing and able to give informed consent for participation in the study
* Not currently taking any regular medications (expect the contraceptive pill)

Exclusion Criteria

* Any past or current Axis 1 DSM-V psychiatric disorder
* Current use of psychoactive medication (except the contraceptive pill, the Depo-Provera injection or the progesterone implant) or medication which may affect the stress response (e.g. corticosteroids, beta-blockers)
* Current or past history of drug or alcohol dependency
* History of current significant neurological condition (e.g. epilepsy) or heart disease/hypertension
* Known hypersensitivity to the study drug
* Currently pregnant or breast feeding
* Previous participation in a study that uses the same or similar computer tasks as those used in the present study
* Previous participation in a study that involves the use of a medication within the last three months
* Significant medical condition
* Smokers consuming \> 5 cigarettes per day
* Individuals consuming \> 6 caffeinated drinks per day
* Lactose Intolerance (due to the study involving administration of a lactose placebo tablet)

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes